Aurinia sets November 3 results. Aurinia Pharmaceuticals stock sits 13.35 percent below its high

Published on 10/20/2026 at 20:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Aurinia sets November 3 results with USD 83.61 million expected. Aurinia Pharmaceuticals stock costs EUR 14.87 on October 20, 2026 at 8:44 p.m. CEST.

November results and valuation

Aurinia set November 3, 2026 for its third-quarter results.
The revenue estimate is USD 83.61 million for the third quarter.
Aurinia Pharmaceuticals stock was trading at EUR 14.87 at Lang & Schwarz on October 20, 2026 at 8:44 p.m. CEST.
The company had USD 2.2 billion in market capitalization as of October 20, 2026.

AUR, CA05156V1022, Illustration mit AI erstellt.

Aurinia Pharmaceuticals (ISIN CA05156V1022) has set November 3, 2026 for its third-quarter results, with analysts expecting USD 83.61 million in revenue. MarketBeat lists the announcement before the market opens and the conference call for 8:30 a.m. ET. Aurinia Pharmaceuticals was trading at EUR 14.87 at Lang & Schwarz on October 20, 2026 at 8:44 p.m. CEST.

November 3 carries a higher estimate

The upcoming report is expected to show revenue growth from USD 73.47 million in the same quarter a year earlier to USD 83.61 million. That is a 13.81 percent increase. The consensus earnings estimate is USD 0.22 per share, compared with USD 0.23 per share a year earlier, according to MarketBeat.

The stock stays below its yearly high

Market data dated October 19, 2026 put Aurinia Pharmaceuticals stock in a USD 11.39 to USD 19.25 52-week range. The latest USD 16.68 Nasdaq quotation on October 20 was 13.35 percent below the upper end of that range. The company had a USD 2.2 billion market capitalization and a trailing P/E ratio of 7.29 on October 20.

What matters before the report?

The second-quarter comparison provides the clearest operating baseline. Aurinia reported USD 58.57 million in revenue and USD 0.28 in earnings per share for the quarter ended June 30, 2026, while the revenue estimate cited by MarketBeat was USD 80.45 million and the earnings estimate was USD 0.24. The revenue shortfall was paired with an earnings beat of USD 0.04 per share. MarketBeat reported those figures on October 16, 2026.

Biotechnology peers provide scale

BioMarin Pharmaceutical stock was at USD 55.97 on October 20, 2026, up 2.38 percent, with a USD 10.8 billion market capitalization and a P/E ratio of 143.54. Shattuck Labs stock was at USD 5.83, up 8.47 percent, with a USD 584.6 million market capitalization and a negative P/E ratio of 11.41.

Dates and company profile

The next dated corporate event is the November 3, 2026 third-quarter announcement. Aurinia develops therapies for autoimmune diseases and markets LUPKYNIS, an approved oral treatment for adult patients with active lupus nephritis, according to its investor relations page.

Price and investor view

The November report will put the USD 83.61 million revenue estimate against the USD 73.47 million prior-year comparison, while the latest quotation remains below the USD 19.25 yearly high. Aurinia Pharmaceuticals was trading at EUR 14.87 at Lang & Schwarz on October 20, 2026 at 8:44 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Aurinia Pharmaceuticals stock.